Pentanoic acid, 5-(dipentylamino)-5-oxo-4-((3-quinolinylcarbonyl)amino)-, (R)- | 119295-94-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Pentanoic acid, 5-(dipentylamino)-5-oxo-4-((3-quinolinylcarbonyl)amino)-, (R)-
• 英文别名: (4R)-5-(dipentylamino)-5-oxo-4-(quinoline-3-carbonylamino)pentanoic acid
• CAS: 119295-94-2
• 化学式: C₂₅H₃₅N₃O₄
• 分子量: 441.6
• InChiKey: LVIZXRRZYVZZEN-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Treatment of maladaptive substance use with cholecystokinin (CCK) antagonists
  申请人：Mitchell Jennifer

  公开号：US20060258647A1

  公开（公告）日：2006-11-16

  The present invention provides a method of mitigating a symptom of maladaptive substance use in a subject by inhibiting CCK B receptors. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a symptom of maladaptive substance use. Methods of the invention can involve assaying test agent binding to CCK B receptors. Alternatively, test agents can be screened for their ability to alter the level of CCK B receptor polypeptides, polynucleotides, or function. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for maladaptive substance use based on comparison to the corresponding level for a control population.